Skip to main navigation Skip to search Skip to main content

Overexpression of urokinase-type plasminogen activator in pancreatic adenocarcinoma is regulated by constitutively activated RelA

  • Weixin Wang
  • , James L. Abbruzzese
  • , Douglas B. Evans
  • , Paul J. Chiao

Research output: Contribution to journalArticlepeer-review

Abstract

The Rel/NF-κB transcription factors regulate the expression of many genes. The activity of RelA, a member of the Rel/NF-κB transcription factor family, is constitutively activated in the majority of pancreatic adenocarcinomas and cell lines. We report that the urokinase-type plasminogen activator (uPA), one of the critical proteases involved in tumor invasion and metastasis, is overexpressed in pancreatic tumor cells and its overexpression is induced by constitutive RelA activity. The uPA promoter contains an NF-κB binding site that directly mediates the induction of uPA expression by RelA. Expression of a dominant-negative IκBα mutant inhibits κB site-dependent transcriptional activation of a uPA promoter-CAT reporter gene. Treating the pancreatic tumor cell lines with the known NF-κB inhibitors, dexamethasone and n-tosylphenyalanine chloromethyl ketone (TPCK), abolishes constitutive RelA activity and uPA overexpression. These results show that uPA is one of the downstream target genes induced by constitutively activated RelA in human pancreatic tumor cells, and suggests that constitutive RelA activity may play a critical role in tumor invasion and metastasis. Inhibition of constitutive RelA in pancreatic tumor cells may reduce their invasive and metastatic potential.

Original languageEnglish (US)
Pages (from-to)4554-4563
Number of pages10
JournalOncogene
Volume18
Issue number32
DOIs
StatePublished - Aug 12 1999

Keywords

  • NF-κB
  • Pancreatic adenocarcinoma
  • Urokinase-type plasminogen activator

ASJC Scopus subject areas

  • Molecular Biology
  • Genetics
  • Cancer Research

Fingerprint

Dive into the research topics of 'Overexpression of urokinase-type plasminogen activator in pancreatic adenocarcinoma is regulated by constitutively activated RelA'. Together they form a unique fingerprint.

Cite this